| abstract |
The present invention relates to novel carboxylic acid derivatives of formula (I) wherein R1 is tetrazolyl or a group of formula (a); R2 is hydrogen, halogen, hydroxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, alkylthio or CR2 CR10 closes a 5- or 6-membered ring closure; X and Y are nitrogen or methine; Z is nitrogen or CR10 (R10 = H or alkyl) or CR10 together with CR2 or CR3 form an optionally substituted 5- or 6-membered alkylene or alkenylene ring; R3 is hydrogen, halogen, hydroxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, alkyl -thio or CR3 is closed with CR10 to form a 5- or 6-membered ring; R4 and R5 are optionally substituted cycloalkyl, phenyl or naphthyl, or phenyl or naphthyl groups which, in the ortho position, have a chemical bond, a -CH2-, -CH2-CH2-, -CH = CH-, -O-, - S -, - SO2-, -NH- or -N (alkyl) -; R6 is optionally substituted cycloalkyl, phenyl, naphthyl or 5- or 6-membered heteroaromatic; W is sulfur or oxygen; Q is a space element corresponding to a C2-C4 alkylene chain length - and their use as active ingredients in pharmaceutical compositions for the treatment of diseases associated with elevated endothelin levels. (a) Oh |